Tafinlar
Dabrafenib · Novartis Pharmaceuticals Corporation
CANCER MEDICINE · PRESCRIPTION ONLY (USA)Tafinlar ingredients
| Active ingredient | Strength |
|---|---|
| Dabrafenib Mesylate | 10 mg/1, 50 mg/1, 75 mg/1 |
What Tafinlar is used for
Tafinlar is a cancer medicine (kinase inhibitor). Its approved uses are listed on the official FDA label below.
Key facts
- Brand
- Tafinlar
- Generic name
- Dabrafenib
- Made by
- Novartis Pharmaceuticals Corporation
- Forms
- Capsule, Tablet, For Suspension
- Given
- Oral
- Drug class
- Kinase Inhibitor
- FDA approval
- New drug application (NDA) NDA217514
- On the US market since
- 2016
Official information
- Tafinlar prescribing information (FDA label) on DailyMed
- MedlinePlus drug information (search for Dabrafenib)
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Tafinlar?
Tafinlar (Dabrafenib) is a cancer medicine made by Novartis Pharmaceuticals Corporation, approved by the US FDA.
What are the ingredients of Tafinlar?
Tafinlar contains Dabrafenib Mesylate (10 mg/1, 50 mg/1, 75 mg/1).
From the FDA National Drug Code directory (open.fda.gov, public domain). Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA